Arcus Capital Partners LLC Invests $321,000 in Medpace Holdings, Inc.

Arcus Capital Partners LLC has recently obtained a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter of the year. According to a recent filing with the SEC, the firm purchased 965 shares of Medpace stock, which amounts to an investment of approximately $321,000.

Recent Investor Activity

In addition to Arcus Capital's investment, other institutional investors have also shown interest in Medpace by adjusting their holdings. R Squared Ltd established a new stake in the company valued at about $30,000 in the fourth quarter. Stone House Investment Management LLC invested around $33,000 in the third quarter, while Ashton Thomas Securities LLC also acquired shares worth approximately $37,000 during the same period. Capital Performance Advisors LLP made a new investment of $46,000 in the third quarter. Moreover, True Wealth Design LLC notably increased its position in Medpace by 16,800% in the third quarter, resulting in ownership of 169 shares valued at $56,000 after acquiring an additional 168 shares recently. Currently, institutional investors collectively own 77.98% of Medpace's stock.

Analyst Opinions and Ratings

Several analysts have provided recent updates regarding Medpace's stock. For example, William Blair reaffirmed an "outperform" rating on Medpace shares in a research note issued on October 22. In a different report, Robert W. Baird increased their price target from $354.00 to $362.00, maintaining a "neutral" rating. Meanwhile, Baird R W adjusted their rating from a "strong-buy" to a "hold" on October 23. TD Cowen also revised their target price from $413.00 to $372.00 while assigning a "buy" rating. Among analysts, seven have issued a hold rating, and five have rated the company as a buy, leading to an average rating of "Hold" with a consensus price target of $381.44, according to MarketBeat.com.

Current Stock Performance

On a recent trading day, Medpace (NASDAQ:MEDP) opened at $342.41. The company's market capitalization is around $10.64 billion, with a price-to-earnings (P/E) ratio of 29.98, a price/earnings growth (PEG) ratio of 1.85, and a beta of 1.36. Over the past year, Medpace's stock has fluctuated significantly, with a low of $302.01 and a high of $459.77. The fifty-day moving average price stands at $343.70, and the 200-day moving average price is $348.88.

Medpace most recently announced its earnings results on February 10, reporting earnings of $3.67 per share (EPS) for the quarter. This result exceeded the consensus estimate of $2.96 per share by $0.71. The company recorded a net margin of 17.66% and a return on equity (ROE) of 50.87%. Analysts anticipate Medpace will report 11.93 EPS for the current fiscal year.

About Medpace Holdings, Inc.

Medpace Holdings, Inc. specializes in providing outsourced clinical development services to the biotechnology, pharmaceutical, and medical device sectors. Its comprehensive services encompass medical department support, clinical trial management, patient recruitment and retention, medical writing, data sciences, pharmacovigilance, regulatory affairs, and more.

Conclusion

This recent investment by Arcus Capital and the activities of other institutional investors underline the growing interest in Medpace Holdings, Inc., amid their positive financial performance and favorable analyst ratings. As investors watch closely, the future trajectory of Medpace remains a topic of discussion.

investment, stocks, analysis